Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

One of the motivations for this kind of work is to assist genetic epidemiology, or population-wide genetic studies. Indeed, this is one of the main goals of Glaxo Smith-Kline, which participates in the study, says Novembre. “They are interested in pharmacogenetic purposes to do case control studies of adverse drug reactions,” he says.

“The idea is to save money in these large-scale genetic epidemiological studies,” says Krawczak. “It’s very costly to genotype people.” But if you can create genetic control groups for distinct populations, it allows you to more easily test drugs against different populations to see where the benefits lie, he says.

At the moment, the main focus is on Europe because it has a lot of genetic variation but a relatively well defined and delineated history. “It’s a nightmare to do population genetics in America,” says Krawczak. “There are so many migrant populations from different parts of the world that it’s just too complex.”

Even so, Novembre says that he plans to extend this sort of research to cover larger parts of the world and individuals of mixed ancestry. “At the moment, if you have mixed grandparent ancestry you appear between the set of countries where the grandparents come from,” he says. “So if they are part Italian and part British, they would appear in Switzerland. But we are working on algorithms that will be able to infer grandparent ancestry and get around this.”

Eventually, this sort of research is likely to be picked up by the growing number of companies offering DNA home tests over the Internet to people wishing to trace their genealogy. At the moment, these services tend to offer fairly rough pictures of one’s origins. But as the microarray technology becomes cheaper and the statistical software used to map it becomes more sophisticated, these kinds of services should greatly improve, Novembre says.

8 comments. Share your thoughts »

Credit: John Novembre

Tagged: Biomedicine, genetics, diseases, genome analysis, ancestory, Affymetrix, genetic mapping

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me
×

A Place of Inspiration

Understand the technologies that are changing business and driving the new global economy.

September 23-25, 2014
Register »